Professor Jack Cuzick
CBE, PhD, FRS, FMedSci, FRCP (hon)
Director, Wolfson Institute of Preventive Medicine
Centre Lead, Research Theme Lead
Research Focus
I am the Director of Wolfson Institute of Preventive Medicine and also Head of Centre for Cancer Prevention. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.
Key Publications
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658
A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741
Major Funding
- 2018-2023- CRUK, Catalyst, £1.4M
- 2017-2020- Barts Charity, Preventative Neurology, £1.5M
- 2014-2019- CRUK, Cancer Prevention, £6.9M
- 2007-2019- CRUK, IBIS II, £2M
Other Activities
- Fellow of the Academy of Medical Sciences
- Fellow of the Royal Society
- Science Strategy Committee member for Breast Cancer Now
- Research Strategy Group member for Prostate Cancer UK
Research
I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.
I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.
I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.
Other Activities
- Fellow of the Academy of Medical Sciences
- Fellow of the Royal Society
- Science Strategy Committee member for Breast Cancer Now
- Research Strategy Group member for Prostate Cancer UK
Major Funding
- 2018-2023- CRUK, Catalyst, £1.4M
- 2017-2020- Barts Charity, Preventative Neurology, £1.5M
- 2014-2019- CRUK, Cancer Prevention, £6.9M
- 2007-2019- CRUK, IBIS II, £2M
Recent Publications
Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Landy R, Sasieni PD, Mathews C et al. Int J Cancer (2020) 147(2) 887-896
https://www.ncbi.nlm.nih.gov/pubmed/31837006
Prognostic Value of EndoPredict in Women with Hormone Receptor Positive, HER2-Negative Invasive Lobular Breast Cancer. Sestak I, Filipits M, Buus R et al. Clin Cancer Res (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32561662
What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420) French DP, Astley S, Astley S et al. BMC Cancer (2020) 20(7)
Key steps for effective breast cancer prevention. Britt KL, Cuzick J, Phillips K-A Nat Rev Cancer (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32528185
Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus-positive women in Mexico. Ramírez-Palacios P, Chen A, Flores YN et al. Cancer Cytopathol (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32520446
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Kyrgiou M, Arbyn M, Bergeron C et al. Br J Cancer (2020) (2)
https://www.ncbi.nlm.nih.gov/pubmed/32507855
Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Castle PE, Adcock R, Cuzick J et al. Arch Pathol Lab Med (2020) 144(2) 725-734
https://www.ncbi.nlm.nih.gov/pubmed/31718233
Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom) Renehan AG, Pegington M, Harvie MN et al. British Journal of Cancer (2020) 122(7) 1552-1561
A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density Brentnall AR, van Veen EM, Harkness EF et al. International Journal of Cancer (2020) 146(7) 2122-2129
10-year results of the International Breast Cancer Intervention Study II (IBIS-II) Cuzick J, Sestak I, Forbes JF et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(1) 527-527
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000519166100027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a
Biography
I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.
I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.